MEDIUM confidence: 100% data completeness, but the composite (59) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-09-27.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $7M— | $3M-58.4% | $234M+8290.0% | $329M+40.8% | $616M+87.3% |
| EPS (dil.) | $-2.63— | $-1.46n/m | $0.09n/m | $0.15+75.8% | $2.77+1746.7% |
| Free Cash Flow | -$296M— | -$176Mn/m | -$31Mn/m | -$41Mn/m | -$25Mn/m |
| Gross Margin | 88.2% | 90.5%+2.3pp | 94.0%+3.5pp | 88.3%-5.7pp | 83.7%-4.6pp |
| Operating Margin | -5154.3% | -7839.0%-2684.7pp | 8.8%+7847.8pp | 12.7%+3.9pp | 20.0%+7.3pp |
| Net Margin | -5204.1% | -8036.3%-2832.3pp | 5.4%+8041.8pp | 7.1%+1.7pp | 72.6%+65.5pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$275K over 180 days (0 open-market buys, 1 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Buy-rated share 78% → 88% over ~3 months (+10pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $0.31 | $0.05 | -83.6% |
| May 2026 | $0.23 | $0.14 | -39.1% |
| Feb 2026 | $0.35 | $0.14 | -60.0% |
| Nov 2025 | $0.24 | $2.43 | +912.5% |
| Aug 2025 | $0.32 | $0.17 | -46.9% |
| May 2025 | $0.18 | $0.03 | -83.3% |
| Mar 2025 | $0.08 | $0.15 | +87.5% |
| Nov 2024 | $0.03 | $0.02 | -33.3% |
The QScore of 59 for TG Therapeutics indicates a moderately favorable outlook, driven by strong growth and momentum scores, with the company exhibiting high revenue and EPS growth of 87.3% and 1837.5%, respectively, and a 12-month return of 81.2%. The value score is a drag on the overall QScore, as the stock trades at a premium with a P/E of 20.1 and EV/EBITDA of 71.8. The short-term score is slightly higher than the long-term score, suggesting some near-term optimism, with the stock's momentum and growth metrics contributing to this divergence.